Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2011

Open Access 01-12-2011 | Research

Autotaxin is induced by TSA through HDAC3 and HDAC7 inhibition and antagonizes the TSA-induced cell apoptosis

Authors: Song Li, Baolu Wang, Yan Xu, Junjie Zhang

Published in: Molecular Cancer | Issue 1/2011

Login to get access

Abstract

Background

Autotaxin (ATX) is a secreted glycoprotein with the lysophospholipase D (lysoPLD) activity to convert lysophosphatidylcholine (LPC) into lysophosphatidic acid (LPA), a bioactive lysophospholipid involved in diverse biological actions. ATX is highly expressed in some cancer cells and contributes to their tumorigenesis, invasion, and metastases, while in other cancer cells ATX is silenced or expressed at low level. The mechanism of ATX expression regulation in cancer cells remains largely unknown.

Results

In the present study, we demonstrated that trichostatin A (TSA), a well-known HDAC inhibitor (HDACi), significantly induced ATX expression in SW480 and several other cancer cells with low or undetectable endogenous ATX expression. ATX induction could be observed when HDAC3 and HDAC7 were down-regulated by their siRNAs. It was found that HDAC7 expression levels were low in the cancer cells with high endogenous ATX expression. Exogenous over-expression of HDAC7 inhibited ATX expression in these cells in a HDAC3-dependent manner. These data indicate that HDAC3 and HDAC7 collaboratively suppress ATX expression in cancer cells, and suggest that TSA induce ATX expression by inhibiting HDAC3 and HDAC7. The biological significance of this regulation mechanism was revealed by demonstrating that TSA-induced ATX protected cancer cells against TSA-induced apoptosis by producing LPA through its lysoPLD activity, which could be reversed by BrP-LPA and S32826, the inhibitors of the ATX-LPA axis.

Conclusions

We have demonstrated that ATX expression is repressed by HDAC3 and HDAC7 in cancer cells. During TSA treatment, ATX is induced due to the HDAC3 and HDAC7 inhibition and functionally antagonizes the TSA-induced apoptosis. These results reveal an internal HDACi-resistant mechanism in cancer cells, and suggest that the inhibition of ATX-LPA axis would be helpful to improve the efficacy of HDACi-based therapeutics against cancer.
Appendix
Available only for authorised users
Literature
1.
Stracke ML, Krutzsch HC, Unsworth EJ, Arestad A, Cioce V, Schiffmann E, Liotta LA: Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein. J Biol Chem. 1992, 267: 2524-2529.PubMed
2.
Jansen S, Stefan C, Creemers JW, Waelkens E, Van Eynde A, Stalmans W, Bollen M: Proteolytic maturation and activation of autotaxin (NPP2), a secreted metastasis-enhancing lysophospholipase D. J Cell Sci. 2005, 118: 3081-3089. 10.1242/jcs.02438CrossRefPubMed
3.
4.
Umezu-Goto M, Kishi Y, Taira A, Hama K, Dohmae N, Takio K, Yamori T, Mills GB, Inoue K, Aoki J, Arai H: Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol. 2002, 158: 227-233. 10.1083/jcb.200204026PubMedCentralCrossRefPubMed
5.
Jansen S, Andries M, Vekemans K, Vanbilloen H, Verbruggen A, Bollen M: Rapid clearance of the circulating metastatic factor autotaxin by the scavenger receptors of liver sinusoidal endothelial cells. Cancer Lett. 2009, 284: 216-221. 10.1016/j.canlet.2009.04.029CrossRefPubMed
6.
van Meeteren LA, Ruurs P, Stortelers C, Bouwman P, van Rooijen MA, Pradere JP, Pettit TR, Wakelam MJ, Saulnier-Blache JS, Mummery CL, Moolenaar WH, Jonkers J: Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development. Mol Cell Biol. 2006, 26: 5015-5022. 10.1128/MCB.02419-05PubMedCentralCrossRefPubMed
7.
Tanaka M, Okudaira S, Kishi Y, Ohkawa R, Iseki S, Ota M, Noji S, Yatomi Y, Aoki J, Arai H: Autotaxin stabilizes blood vessels and is required for embryonic vasculature by producing lysophosphatidic acid. J Biol Chem. 2006, 281: 25822-25830. 10.1074/jbc.M605142200CrossRefPubMed
8.
Moolenaar WH, van Meeteren LA, Giepmans BN: The ins and outs of lysophosphatidic acid signaling. Bioessays. 2004, 26: 870-881. 10.1002/bies.20081CrossRefPubMed
9.
Noguchi K, Herr D, Mutoh T, Chun J: Lysophosphatidic acid (LPA) and its receptors. Curr Opin Pharmacol. 2009, 9: 15-23. 10.1016/j.coph.2008.11.010CrossRefPubMed
10.
Luquain C, Sciorra VA, Morris AJ: Lysophosphatidic acid signaling: how a small lipid does big things. Trends Biochem Sci. 2003, 28: 377-383. 10.1016/S0968-0004(03)00139-7CrossRefPubMed
11.
Georas SN: Lysophosphatidic acid and autotaxin: emerging roles in innate and adaptive immunity. Immunol Res. 2009, 45: 229-238. 10.1007/s12026-009-8104-y. 10.1007/s12026-009-8104-yCrossRefPubMed
12.
Fotopoulou S, Oikonomou N, Grigorieva E, Nikitopoulou I, Paparountas T, Thanassopoulou A, Zhao Z, Xu Y, Kontoyiannis DL, Remboutsika E, Aidinis V: ATX expression and LPA signalling are vital for the development of the nervous system. Dev Bio. 2010, 399: 451-64l. 10.1016/j.ydbio.2010.01.007. 10.1016/j.ydbio.2010.01.007CrossRef
13.
Ptaszynska MM, Pendrak ML, Stracke ML, Roberts DD: Autotaxin signaling via lysophosphatidic acid receptors contributes to vascular endothelial growth factor-induced endothelial cell migration. Mol Cancer Res. 2010, 8: 309-321. 10.1158/1541-7786.MCR-09-0288PubMedCentralCrossRefPubMed
14.
Im E, Motiejunaite R, Aranda J, Park EY, Federico L, Kim TI, Clair T, Stracke ML, Smyth S, Kazlauskas A: PLC{gamma} activation drives increased production of autotaxin in endothelial cells and LPA-dependent regression. Mol Cell Biol. 2010, 30: 2401-2410. 10.1128/MCB.01275-09PubMedCentralCrossRefPubMed
15.
van Meeteren LA, Moolenaar WH: Regulation and biological activities of the autotaxin-LPA axis. Prog Lipid Res. 2007, 46: 145-160. 10.1016/j.plipres.2007.02.001CrossRefPubMed
16.
Nam SW, Clair T, Campo CK, Lee HY, Liotta LA, Stracke ML: Autotaxin (ATX), a potent tumor motogen, augments invasive and metastatic potential of ras-transformed cells. Oncogene. 2000, 19: 241-247. 10.1038/sj.onc.1203263CrossRefPubMed
17.
Chen M, O'Connor KL: Integrin alpha6beta4 promotes expression of autotaxin/ENPP2 autocrine motility factor in breast carcinoma cells. Oncogene. 2005, 24: 5125-5130. 10.1038/sj.onc.1208729CrossRefPubMed
18.
Liu S, Umezu-Goto M, Murph M, Lu Y, Liu W, Zhang F, Yu S, Stephens LC, Cui X, Murrow G, Coombes K, Muller W, Hung MC, Perou CM, Lee AV, Fang X, Mills GB: Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. Cancer Cell. 2009, 15: 539-550. 10.1016/j.ccr.2009.03.027PubMedCentralCrossRefPubMed
19.
Vidot S, Witham J, Agarwal R, Greenhough S, Bamrah HS, Tigyi GJ, Kaye SB, Richardson A: Autotaxin delays apoptosis induced by carboplatin in ovarian cancer cells. Cell Signal. 2010, 22: 926-935. 10.1016/j.cellsig.2010.01.017CrossRefPubMed
20.
Samadi N, Gaetano C, Goping IS, Brindley DN: Autotaxin protects MCF-7 breast cancer and MDA-MB-435 melanoma cells against Taxol-induced apoptosis. Oncogene. 2009, 28: 1028-1039. 10.1038/onc.2008.442CrossRefPubMed
21.
North EJ, Howard AL, Wanjala IW, Pham TC, Baker DL, Parrill AL: Pharmacophore development and application toward the identification of novel, small-molecule autotaxin inhibitors. J Med Chem. 2010, 53: 3095-3105. 10.1021/jm901718zCrossRefPubMed
22.
Wu JM, Xu Y, Skill NJ, Sheng H, Zhao Z, Yu M, Saxena R, Maluccio MA: Autotaxin expression and its connection with the TNF-alpha-NF-kappaB axis in human hepatocellular carcinoma. Mol Cancer. 2010, 9: 71- 10.1186/1476-4598-9-71PubMedCentralCrossRefPubMed
23.
Kishi Y, Okudaira S, Tanaka M, Hama K, Shida D, Kitayama J, Yamori T, Aoki J, Fujimaki T, Arai H: Autotaxin is overexpressed in glioblastoma multiforme and contributes to cell motility of glioblastoma by converting lysophosphatidylcholine to lysophosphatidic acid. J Biol Chem. 2006, 281: 17492-17500. 10.1074/jbc.M601803200CrossRefPubMed
24.
Witt O, Deubzer HE, Milde T, Oehme I: HDAC family: What are the cancer relevant targets?. Cancer Lett. 2009, 277: 8-21. 10.1016/j.canlet.2008.08.016CrossRefPubMed
25.
26.
27.
Prince HM, Bishton MJ, Harrison SJ: Clinical studies of histone deacetylase inhibitors. Clin Cancer Res. 2009, 15: 3958-3969. 10.1158/1078-0432.CCR-08-2785CrossRefPubMed
28.
Bolden JE, Peart MJ, Johnstone RW: Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006, 5: 769-784. 10.1038/nrd2133CrossRefPubMed
29.
Lane AA, Chabner BA: Histone deacetylase inhibitors in cancer therapy. J Clin Oncol. 2009, 27: 5459-5468. 10.1200/JCO.2009.22.1291CrossRefPubMed
30.
Wilson AJ, Chueh AC, Togel L, Corner GA, Ahmed N, Goel S, Byun DS, Nasser S, Houston MA, Jhawer M, Smarrt HJ, Murray LB, Nicholas C, Heerdt BG, Arango D, Augenlicht LH, Mariadason JM: Apoptotic sensitivity of colon cancer cells to histone deacetylase inhibitors is mediated by an Sp1/Sp3-activated transcriptional program involving immediate-early gene induction. Cancer Res. 2010, 70: 609-620. 10.1158/0008-5472.CAN-09-2327PubMedCentralCrossRefPubMed
31.
Prestwich GD, Gajewiak J, Zhang H, Xu X, Yang G, Serban M: Phosphatase-resistant analogues of lysophosphatidic acid: agonists promote healing, antagonists and autotaxin inhibitors treat cancer. Biochim Biophys Acta. 2008, 1781: 588-594.PubMedCentralCrossRefPubMed
32.
Zhang H, Xu X, Gajewiak J, Tsukahara R, Fujiwara Y, Liu J, Fells JI, Perygin D, Parrill AL, Tigyi G, Prestwich GD: Dual activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor reduces breast cancer cell migration in vitro and causes tumor regression in vivo. Cancer Res. 2009, 69: 5441-5449. 10.1158/0008-5472.CAN-09-0302PubMedCentralCrossRefPubMed
33.
Xu X, Yang G, Zhang H, Prestwich GD: Evaluating dual activity LPA receptor pan-antagonist/autotaxin inhibitors as anti-cancer agents in vivo using engineered human tumors. Prostaglandins Other Lipid Mediat. 2009, 89: 140-146. 10.1016/j.prostaglandins.2009.07.006PubMedCentralCrossRefPubMed
34.
Ferry G, Moulharat N, Pradere JP, Desos P, Try A, Genton A, Giganti A, Beucher-Gaudin M, Lonchampt M, Bertrand M, Saulnier Blache JS, Tucker GC, Cordi A, Boutin JA: S32826, a nanomolar inhibitor of autotaxin: discovery, synthesis and applications as a pharmacological tool. J Pharmacol Exp Ther. 2008, 327: 809-819. 10.1124/jpet.108.141911CrossRefPubMed
35.
Fischle W, Dequiedt F, Fillion M, Hendzel MJ, Voelter W, Verdin E: Human HDAC7 histone deacetylase activity is associated with HDAC3 in vivo. J Biol Chem. 2001, 276: 35826-35835. 10.1074/jbc.M104935200CrossRefPubMed
36.
Ptaszynska MM, Pendrak ML, Bandle RW, Stracke ML, Roberts DD: Positive feedback between vascular endothelial growth factor-A and autotaxin in ovarian cancer cells. Mol Cancer Res. 2008, 6: 352-363. 10.1158/1541-7786.MCR-07-0143PubMedCentralCrossRefPubMed
37.
Bachner D, Ahrens M, Schroder D, Hoffmann A, Lauber J, Betat N, Steinert P, Flohe L, Gross G: Bmp-2 downstream targets in mesenchymal development identified by subtractive cloning from recombinant mesenchymal progenitors (C3H10T1/2). Dev Dyn. 1998, 213: 398-411. 10.1002/(SICI)1097-0177(199812)213:4<398::AID-AJA5>3.0.CO;2-TCrossRefPubMed
38.
Wang S, Li X, Parra M, Verdin E, Bassel-Duby R, Olson EN: Control of endothelial cell proliferation and migration by VEGF signaling to histone deacetylase 7. Proc Natl Acad Sci USA. 2008, 105: 7738-7743. 10.1073/pnas.0802857105PubMedCentralCrossRefPubMed
39.
Jensen ED, Gopalakrishnan R, Westendorf JJ: Bone morphogenic protein 2 activates protein kinase D to regulate histone deacetylase 7 localization and repression of Runx2. J Biol Chem. 2009, 284: 2225-2234. 10.1074/jbc.M800586200PubMedCentralCrossRefPubMed
40.
Zhong S, Goto H, Inagaki M, Dong Z: Phosphorylation at serine 28 and acetylation at lysine 9 of histone H3 induced by trichostatin A. Oncogene. 2003, 22: 5291-5297. 10.1038/sj.onc.1206507CrossRefPubMed
41.
Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK: Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer. 2001, 1: 194-202. 10.1038/35106079CrossRefPubMed
42.
Fantin VR, Richon VM: Mechanisms of resistance to histone deacetylase inhibitors and their therapeutic implications. Clin Cancer Res. 2007, 13: 7237-7242. 10.1158/1078-0432.CCR-07-2114CrossRefPubMed
43.
East JE, Kennedy AJ, Tomsig JL, De Leon AR, Lynch KR, Macdonald TL: Synthesis and structure-activity relationships of tyrosine-based inhibitors of autotaxin (ATX). Bioorg Med Chem Lett. 2010, 20: 7132-7136. 10.1016/j.bmcl.2010.09.030PubMedCentralCrossRefPubMed
44.
Albers HM, van Meeteren LA, Egan DA, van Tilburg EW, Moolenaar WH, Ovaa H: Discovery and optimization of boronic acid based inhibitors of autotaxin. J Med Chem. 53: 4958-4967.
45.
Cavalli S, Houben AJ, Albers HM, van Tilburg EW, de Ru A, Aoki J, van Veelen P, Moolenaar WH, Ovaa H: Development of an Activity-Based Probe for Autotaxin. Chembiochem. 2010, 11: 2311-2317. 10.1002/cbic.201000349CrossRefPubMed
46.
Li X, Song S, Liu Y, Ko SH, Kao HY: Phosphorylation of the histone deacetylase 7 modulates its stability and association with 14-3-3 proteins. J Biol Chem. 2004, 279: 34201-34208. 10.1074/jbc.M405179200CrossRefPubMed
47.
Zhang X, Ozawa Y, Lee H, Wen YD, Tan TH, Wadzinski BE, Seto E: Histone deacetylase 3 (HDAC3) activity is regulated by interaction with protein serine/threonine phosphatase 4. Genes Dev. 2005, 19: 827-839. 10.1101/gad.1286005PubMedCentralCrossRefPubMed
48.
Li S, Zhang J: Lipopolysaccharide induces autotaxin expression in human monocytic THP-1 cells. Biochem Biophys Res Commun. 2009, 378: 264-268. 10.1016/j.bbrc.2008.11.047CrossRefPubMed
49.
Mariadason JM, Arango D, Shi Q, Wilson AJ, Corner GA, Nicholas C, Aranes MJ, Lesser M, Schwartz EL, Augenlicht LH: Gene expression profiling-based prediction of response of colon carcinoma cells to 5-fluorouracil and camptothecin. Cancer Res. 2003, 63: 8791-8812.PubMed
Metadata
Title
Autotaxin is induced by TSA through HDAC3 and HDAC7 inhibition and antagonizes the TSA-induced cell apoptosis
Authors
Song Li
Baolu Wang
Yan Xu
Junjie Zhang
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2011
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-10-18

Other articles of this Issue 1/2011

Molecular Cancer 1/2011 Go to the issue

Review

Curcumin: A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma

Research

NONO and RALY proteins are required for YB-1 oxaliplatin induced resistance in colon adenocarcinoma cell lines

Research

Functional analysis of HOXD9 in human gliomas and glioma cancer stem cells

Research

Anti-tumor effects of fibroblast growth factor-binding protein (FGF-BP) knockdown in colon carcinoma

Research

PAX2 is activated by estradiol in breast cancer cells of the luminal subgroup selectively, to confer a low invasive phenotype

Research

Possible role of death receptor-mediated apoptosis by the E3 ubiquitin ligases Siah2 and POSH
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits